Parexel Expands Model-Based Drug Development Offering

July 9, 2015
Applied Clinical Trials Editorial Staff

Applied Clinical Trials

Parexel announced expanded services and capabilities in model-based drug development (MBDD) through its Quantitative Clinical Development (QCD) group.

 

Parexel announced expanded services and capabilities in model-based drug development (MBDD) through its Quantitative Clinical Development (QCD) group.  The Parexel QCD leverages mathematical models for a quantitative analysis of the relationship between drugs, disease and patients, modeling and simulation can predict a drug’s benefits and adverse effects in a patient population prior to conducting a clinical trial. MBDD can improve the efficiency of clinical development by providing quantitative justification for trial design, dose selection, and decisions during trial execution.

 

Read the full release here.

Related Content:

News